Cargando…
In response to the Letter to the Editor by Romach et al. re our publication “Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels”
Autores principales: | Mohan, H., Guzman Lenis, M., Laurette, E.Y., Tejada, O., Sanghvi, T., Leung, K.-Y., Cahill, L.S., Sled, J.G., Delgado-Olguín, P., Greene, N.D.E., Copp, A.J., Serghides, L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054139/ https://www.ncbi.nlm.nih.gov/pubmed/33862586 http://dx.doi.org/10.1016/j.ebiom.2021.103334 |
Ejemplares similares
-
Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels
por: Mohan, Haneesha, et al.
Publicado: (2020) -
Folate deficiency increases the incidence of dolutegravir-associated foetal defects in a mouse pregnancy model
por: Mohan, Haneesha, et al.
Publicado: (2023) -
Letter to the editor in re: Mohan et al., 2020 ‘dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels’
por: Romach, EH, et al.
Publicado: (2021) -
Spontaneous Epiglottic Hematoma Secondary to Supratherapeutic Anticoagulation
por: Koch, Cody A., et al.
Publicado: (2010) -
A Retrospective Review of Supratherapeutic Modafinil Exposures
por: Carstairs, Shaun D., et al.
Publicado: (2010)